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Abstract
The divergent TGF-β superfamily member, macrophage inhibitory cytokine-1 (MIC-1/
GDF15), is overexpressed by most cancers, including prostate cancer (PCa). Whilst its cir-
culating levels are linked to cancer outcome, the role MIC-1/GDF15 plays in cancer devel-
opment and progression is incompletely understood. To investigate its effect on PCa
development and spread, we have used TRAMP prostate cancer prone mice bearing a
germline deletion of MIC-1/GDF15 (TRAMPMIC-/-). On average TRAMPMIC-/- mice died
about 5 weeks earlier and had larger prostatic tumors compared with TRAMP mice that
were wild type for MIC-1/GDF15 (TRAMPMIC+/+). Additionally, at the time of death or ethical
end point, even when adjusted for lifespan, there were no significant differences in the num-
ber of mice with metastases between the TRAMPMIC+/+ and TRAMPMIC-/- groups. However,
consistent with our previous data, more than twice as many TRAMP mice overexpressing
MIC-1/GDF15 (TRAMPfmsmic-1) had metastases than TRAMPMIC+/+ mice (p<0.0001). We
conclude that germ line gene deletion of MIC-1/GDF15 leads to increased local tumor
growth resulting in decreased survival consistent with an overall protective role for MIC-1/
GDF15 in early primary tumor development. However, in advancing disease, as we have
previously noted, MIC-1/GDF15 overexpression may promote local invasion and
metastatic spread.
Introduction
Prostate cancer (PCa) is one of the most frequently diagnosed cancers in men. It caused an esti-
mated 29,480 deaths in the USA in 2014 and is the second leading cause of cancer deaths in
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men [1]. Despite its clinical importance, our understanding of its biology is incomplete and
aside from surgery for early stage disease, its therapy is palliative. Like most, if not all tumors,
PCa displays altered expression of many gene products, including cytokines and growth fac-
tors. One cytokine commonly overexpressed in many cancers, including PCa, is MIC-1/
GDF15, a divergent member of the transforming growth factor-β superfamily[2]. Expression of
this cytokine is also induced by most cancer therapies and its serum levels are clearly linked to
cancer outcome [3–9].
MIC-1/GDF15 is detectible in the blood of all individuals [10]. Its expression by cancers is
frequently reflected by rises in its blood levels, usually in proportion to the stage and extent of
tumor [5,11–16]. For example, there is a continuing rise in MIC-1/GDF15 serum levels with
progression to colonic polyps, high grade dysplastic polyps, localized colorectal cancer (CRC)
and then disseminated CRC [13]. Further, patients with CRC with elevated serumMIC-1/
GDF15 levels at presentation, have a worse overall prognosis and earlier disease relapse
[13,17]. For PCa, MIC-1/GDF15 serum levels are an independent predictor of the presence of
cancer [14] and in more advanced disease they predict overall survival and bone metastasis
[12,16]. High MIC-1/GDF15 serum levels also predict diagnosis and/or outcome for a wide
range of malignancies including melanoma [18,19], cancers of the pancreas [15,20,21], thyroid
[22,23], ovary [24] and endometrium [25].
In patients with advanced cancers, serum MIC-1/GDF15 levels commonly rise from a nor-
mal mean of about 450pg/ml [13] to 10,000–100,000 pg/ml or more [5] and may cause cancer
anorexia/cachexia [26,27]. This common cancer complication is mediated by actions of
MIC-1/GDF15 on feeding centres in the brain and can be reversed by neutralising antibodies
[26,27]. MIC-1/GDF15 serum levels in cancer are influenced not only by its over-expression,
but also depend on how it is processed by the tumor. Intracellular processing leads to removal
of the MIC-1/GDF15 propeptide and diffusion into the blood stream after secretion. However,
as the propeptide interacts with tumor stroma, unprocessed secreted protein remains bound to
the extracellular matrix proximate to the producing tumor [21,28]. In PCa, increased stromal
MIC-1/GDF15 is associated with better patient outcomes, especially in those with low-grade
localized prostate tumors (Gleason sum score of 6 or less) [28], suggesting that its increased
local availability is beneficial. By contrast, high circulating concentrations of MIC-1/GDF15
are associated with a poor outcome [28]. However, whether MIC-1/GDF15 overexpression in
cancer has a beneficial, harmful or mixed effect on disease outcome is difficult to determine
from epidemiological studies alone.
The in vivo cancer related activity of MIC-1/GDF15, has been examined in a number of
tumor xenograft studies with mixed results. For example, enforced MIC-1/GDF15 overexpres-
sion in HCT-116 colon cancer cells [29] or in the DU145 [30] PCa cell line, xenografted into
immunodeficient mice, reduced tumor size. A tumorigenic glioblastoma cell line, that re-
mained unaffected by MIC-1/GDF15 in vitro, on transfection with MIC-1/GDF15, failed to de-
velop tumors in nude mice [31]. The authors suggested that MIC-1/GDF15 may have acted on
the local tumor microenvironment to inhibit tumor growth. By contrast, knock down of
MIC-1/GDF15 in a human melanoma [18] and a mouse glioblastoma [32] cell line significantly
decreased the growth of engrafted tumors. Further, the xenografts of PC3 PCa cell line engi-
neered to overexpress MIC-1/GDF15 grew faster [33] and when orthotopically implanted, led
to more metastases [34].
Unlike the xenograft models in immunodeficient mice, carcinogen induced and spontane-
ously developing cancer models are performed in immune competent mice, which more closely
mimic the pathogenesis of cancers. In chemically induced cancer models, transgenic overex-
pression of MIC-1/GDF15 leads to resistance to urethane induced lung cancer [35] and azoxy-
methane induced colon cancer [36]. However, whilst transgenic overexpression led to
MIC-1/GDF15 and Prostate Cancer
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protection in these two instances, gene deletion did not modify the development of diethylni-
trosamine induced hepatocellular carcinoma [37].
Spontaneously developing cancers in transgenic mice often most closely conform to human
cancers and all studies based on their use suggest that MIC-1/GDF15 is largely protective in
early disease. Development of large bowel polyps and cancer in Apcmin mice is reduced by
transgenic overexpression of MIC-1/GDF15 [36]. Further, germline deletion of MIC-1/GDF15
in Apcmin mice abolished the protection afforded from the COX inhibitor sulindac [38]. As
this class of drug is known to induce expression of MIC-1/GDF15 in both mice and men [38],
this data suggests that tumor suppression may be dependent on the expression of MIC-1/
GDF15 [38]. Further supporting this view is a study utilising samples from the Polyp Preven-
tion Trial [39]. This demonstrated that non-steroidal anti inflammatory drug (NSAID) users
had a higher serumMIC-1/GDF15 level than non-users and only NSAID users with an elevat-
ed serum MIC-1/GDF15 level were protected from colonic adenoma recurrence [39,40].
More recently we have assessed the effect of MIC-1/GDF15 overexpression on the course of
cancer in Transgenic Adenocarcinoma ofMouse Prostate (TRAMP) prostate cancer prone
transgenic mice. TRAMP mice express SV40 early genes (T and t; Tag) under the control of rat
probasin (rPB) promoter [41], which targets its expression to prostatic epithelium. Heterozy-
gous TRAMP male mice develop progressive prostate cancer exhibiting the same spectrum of
disease as found in men. Over the course of 6–12 months these mice progressively develop lo-
calized then invasive cancer that exhibits metastatic spread to distant sites, primarily the pelvic
lymph nodes, liver, kidney and lungs [42]. Our data indicates that TRAMPmice, overexpres-
sing MIC-1/GDF15, have substantially increased survival due to decreased growth and histo-
logical grade of the primary tumor [43], further supporting a beneficial role for MIC-1/GDF15
in early cancer. However, as the tumor advanced, these mice also developed more metastases
[43], suggesting that MIC-1/GDF15 overexpression may have deleterious actions late in the
course of cancer. There are no other data from transgenic cancer models where the effect of
MIC-1/GDF15 on advanced cancers has been investigated.
It is important to understand the effect that MIC-1/GDF15 has on the biology of cancers as
it is highly overexpressed by many cancers and its expression is induced by cancer therapies.
Thus any effect it has on the biology of cancer is likely to be of clinical significance. To further
advance our understanding of this cytokine in cancer, we have determined how MIC-1/GDF15
deficiency influenced the evolution of PCa. We have utilised TRAMP prostate cancer prone
mice that also bear a germline deletion of the MIC-1/GDF15 gene (TRAMPMIC-/-) or wild type
MIC-1/GDF15 (TRAMPMIC+/+), to compare survival rate, pattern of PCa growth and metastat-
ic spread. TRAMPMIC-/- mice had significantly larger prostate tumors and shorter survival
than TRAMPMIC+/+ mice, but there was no significant difference in the incidence and rate of
metastasis in the two mouse lines suggesting that different mechanisms mediate the effects of
MIC-1/GDF-15 on local and metastatic PCa development. These data are consistent with earli-
er studies, identifying a largely protective role for MIC-1/GDF15 in the local growth of
early cancers.
Materials and Methods
Ethics Statement
All research and animal care procedures were approved by the Garvan Institute/St Vincent’s
Hospital Animal Experimentation Ethics Committee (Ethics No: 07/05, 10/05 and 13/08) and
were in agreement with the Australian Code of Practice for the Care and Use of Animals for
Scientific Purpose.
MIC-1/GDF15 and Prostate Cancer
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Transgenic mice
Heterozygous male TRAMPmice (TRAMP+/-) [41] were generated by mating TRAMP+/- fe-
males (C57BL/6 background) with non-transgenic C57BL/6 males. Mice with a germline dele-
tion of theMIC-1/GDF15 gene (MIC-1-/-) [44], also on a C57BL/6 background were bred with
TRAMPmice to generate MIC-1-/- mice also bearing the TRAMP transgene (TRAMPMIC-/-).
The PB-SV40 T transgene was identified using DNA extracted from tail samples and PCR
primers directed at the PB-SV40 T-antigen sequence: Pb-forward: 5’-CCGGTCGACCG-
GAAGCTTCCACAAGTGCATTTA-3’ and SV40Tag-reverse: 5’-CTCCTTTCAAGACCTA-
GAAGGTCCA-3’. MIC-1/GDF15 gene deletion was identified using primers MIC1Exon2for:
5’-GGCGGCGCACAGCTGGAACTGC-3’ with MIC1Exon2Rev: 5’-CAGCCCCGGGCCAC-
CAGGTCAT-3’ (Wild type pair) and MIC-1/GDF15KOfor: 5’-GAGAGGACTCGAACTCA-
GAACCA-3’ with MIC-1/GDF15KORev: 5’-GAAGTTATATTAAGGGTTCCGCAAGC-3’
(Knock-out pair). Syngeneic mice overexpressing MIC-1/GDF15 under control of the myeloid
cell specific c-fms promoter (MIC-1fms) were used to breed TRAMPmice that also overexpress
MIC-1/GDF15 (TRAMPfmsmic-1). The double transgenic TRAMPfmsmic-1 mice were generated
by crossing TRAMP+/- females with homozygous MIC-1fms males. The MIC-1/GDF15 transgene
in TRAMPfmsmic-1 mice was identified by PCR using primers, Flag-forward: 5’-GACTACAAG-
GACGACGATGACAAG-3’ and MS8-reverse: 5’-CGAAGCCTACCGCGTGCACCGAG-3’.
The reaction conditions used were: denaturation at 95°C for 10 s, annealing at 60°C for 20 s, and
extension at 72°C for 30 s.
Survival study
Based on a statistical power analysis for sample size, (Alpha error = 0.05, statistical
power = 0.95), 35 TRAMPMIC+/+ and 35 TRAMPMIC-/- mice were allocated at 4–6 weeks of
age, for a survival study. From that time, mice were weighed once a week and monitored twice
a week for tumor size and extent by palpating the abdomen. Mice either died or were culled
when they reached ethical end points of tumor size larger than 11mm X 11mm X 11mm, more
than 20% weight loss or meeting any other ethical end point criteria for euthanasia. The overall
survival of individual mice was calculated from birth to ethical end point or death from the
tumor. Survival distribution was estimated using the method of Kaplan-Meier. At necropsy the
genitourinary complex (GU) consisting of prostate (including dorsal, lateral, ventral, and ante-
rior lobes), urethra, ampullary gland, seminal vesicle (SV) and urinary bladder was taken out
and weighed. Prostate was excised from GU and weighed separately. Weight of the GU and
prostate of each mouse was normalized by its body weight (organ wt/body wt).
Primary tumor size
In a separate cohort to that above, prostate tumor growth was compared in TRAMPMIC+/+ and
TRAMPMIC-/- mice. At the start of the study 88 TRAMP and 88 TRAMPMIC-/- mice, 22 of each
for each stage, were pre-allocated to be sacrificed at different time points from early to ad-
vanced tumor stages (8, 17, 25 and 33 weeks of age). For each of the 88 mice necropsied, the
GU was excised and prostate was separated from GU. Total GU and prostate weight were re-
corded and normalized for the donor mouse total body weight (organ wt/body wt).
Identification of tumor metastases
To estimate the occurrence of metastasis at the time of death or culling in TRAMPMIC+/+ and
TRAMPMIC-/- mice, examined a different cohort of TRAMPMIC+/+ (n = 63) and TRAMPMIC-/-
(n = 63). For comparison, we also examined a similar number of MIC-1/GDF15 overexpressing
MIC-1/GDF15 and Prostate Cancer
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TRAMPfmsmic-1 mice (n = 63), whose PCa was known to be associated with increased metasta-
ses [43]. Mice were looked after and euthanized using the same criteria as mentioned above in
the survival study. At the necropsy pelvic lymph nodes, kidney, and liver tumors (if present)
were harvested and fixed in 10% neutral buffered formalin. Lungs were excised, weighed and
fixed in Bouin’s fixative (Sigma-Aldrich) to visualize and count lung tumor colonies. Metastatic
lesions on all the organs were counted under a dissecting microscope. Some of the lesions were
confirmed by H&E staining and further by immunostaining of frozen tissue sections with anti
Tag antibody (Santa Cruz) to confirm the prostatic origin of the tumor. The number of mice
having distant organ metastasis was compared in all the three mouse lines.
Statistical analysis
All graphs and statistical evaluation of all the experiments were performed with GraphPad
Prism software version 6 for Mac OS X, (GraphPad Software, San Diego, CA, USA). Kaplan–
Meier analysis and log-rank statistic were used to compare survival curves. The data for GU
and prostate tumor sizes between groups were compared using 2-way ANOVA or t-test. The
Chi-square test was used for categorical analysis. Statistical power analysis for sample size was
done with the online power and sample size analysis tool (http://www.stat.ubc.ca/) using an
Alpha Error of 0.05 and statistical power level of 0.95. Multivariate logistic regression analysis
was used to examine the relationship of metastasis with survival time. A p value less than 0.05
considered statistically significant.
Results
MIC-1/GDF15 gene deleted TRAMPmice die earlier of PCa
In order to assess the effects of MIC-1/GDF15 gene deletion on the overall survival of TRAMP
mice, we monitored a cohort (n = 35) of TRAMPMIC+/+ and TRAMPMIC-/- mice (Survival
Group) till death or ethical end point. Kaplan-Meier survival analysis showed that TRAMP-
MIC-/- mice had significantly shorter survival than TRAMPMIC+/+ mice (Fig. 1A, p = 0.0416,
log-rank test). The mean survival of 39.5 weeks in TRAMPMIC+/+ mice was reduced by about
5 weeks (34.4 weeks) in the TRAMPMIC-/- group. Further, while only 20% of TRAMPMIC-/-
mice survived at week 40, 42.85% of TRAMPMIC+/+ mice were still alive (Fig. 1A). These data
indicate that germline gene deletion of MIC-1/GDF15 reduced PCa related survival in
TRAMP mice.
TRAMPMIC-/- mice have larger prostate tumors at necropsy
At the necropsy of the above-mentioned survival group of TRAMPMIC+/+ and TRAMPMIC-/-
mice, GU and prostate were isolated and their weights, corrected for body weight, were recorded.
Despite dying earlier than TRAMPMIC+/+ mice, TRAMPMIC-/- mice on average had significantly
heavier prostate tumors at the time of death (Fig. 1C, p = 0.0240). Further, the TRAMPMIC-/-
group had far more mice with very large prostate tumors (normalized prostate weight>10mg/g)
than the TRAMPMIC+/+ group (Fig. 1D, p = 0.0027, Chi-square test). There was no significant
difference in total GU wt (Fig. 1B) between two mouse lines because TRAMPMIC+/+ had signifi-
cantly larger SV tumors than TRAMPMIC-/- mice (data not shown). This data suggests that dele-
tion ofMIC-1/GDF15 gene was associated with increased local prostate tumor growth in
TRAMPmice, perhaps with reduced seminal vesicle invasion.
MIC-1/GDF15 and Prostate Cancer
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MIC-1/GDF15 deletion enhances PCa growth in TRAMPmice
To further assess the impact of MIC-1/GDF15 on prostate cancer growth, at 4–6 weeks of age,
we pre-assigned another cohort of 88 TRAMPMIC+/+ and 88 TRAMPMIC-/- mice to be culled
progressively at four predefined time point up to 33 weeks of age. Consistent with the data
from the survival study group mice, discussed above, there was no significant difference in the
normalized GU weights between two mouse lines at any time point observed (Fig. 2A). When
we looked at the prostate size, there were no detectible differences in the average corrected
prostate weights between TRAMPMIC+/+ and TRAMPMIC-/- mouse lines at week 8 and 17. At
week 25 and 33, TRAMPMIC-/- mice had a 6.9 and 8 fold increase in corrected average prostate
Fig 1. TRAMPMIC-/- mice have shorter survival and larger prostate tumors than TRAMPMIC+/+ mice. (A) Survival data for TRAMPMIC+/+ and TRAMPMIC-/-
mice (n = 35). Overall survival of individual mice from birth to death was plotted using the Kaplan-Meier method. The log-rank statistic for median survival time
is shown. (B) The genitourinary complex (GU) and prostate tumor weights (C), in TRAMPMIC+/+ and TRAMPMIC-/- mice, at the necropsy, are corrected for
body weight and presented as mean ± SEM. Differences are analyzed using an unpaired 2-tailed t test. (D) The number of TRAMPMIC+/+ and TRAMPMIC-/-
mice having large prostate tumor (corrected tumor wt>10mg/g), was compared using a Chi-square test. p values are shown as *, p< 0.05; **, p< 0.01.
doi:10.1371/journal.pone.0115189.g001
MIC-1/GDF15 and Prostate Cancer
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tumor weight respectively, as compared to TRAMPMIC+/+ mice (Fig. 2B) and this difference
was statistically significant at week 33 (p = 0.0098, 2 way ANOVA).
MIC-1/GDF15 gene deletion has no effect on metastases
Since metastasis is the major cause of death in patients with human PCa, we evaluated the ef-
fect ofMIC-1/GDF15 gene deletion on the incidence and extent of metastasis in TRAMP mice.
We examined a separate cohort of 63 TRAMPMIC+/+, 63 TRAMPMIC-/- and 63 MIC-1/GDF15
overexpressing TRAMP (TRAMPfmsmic-1) mice, which were followed until death or ethical end
point. The latter group was included as a positive control, as our previous study had indicated
TRAMPfmsmic-1 mice have more metastases but survive longer [43]. Kaplan-Meier survival
analysis reconfirmed that TRAMPMIC-/- mice die significantly earlier than TRAMPMIC+/+ mice
(Fig. 3A, p = 0.0267, log-rank test), consistent with data in the survival group. Further,
TRAMPfmsmic-1 mice died at significantly slower rate than TRAMPMIC+/+ mice (Fig. 3A,
p<0.0001, log-rank test) confirming data from our previous publication [43]. In this cohort
19% of the TRAMPMIC+/+ mice developed macroscopically detectible distant organ metastasis
in the surveyed organs, which was not significantly different to that of 14.2% in TRAMPMIC-/-
mice (Fig. 3B). The incidence of metastases in these two mouse lines was significantly less that
in TRAMPfmsmic-1 mice, 59% of which developed metastases (Fig. 3B). These data show that al-
though TRAMPMIC-/- mice die significantly earlier than TRAMPMIC+/+ mice (Fig. 3A) there
were no significant differences in the incidence of distant organ metastasis between the two
mouse lines (Fig. 3B). In contrast, as previously reported, a significantly higher proportion of
TRAMPfmsmic-1 mice showed distant organ metastasis compared with TRAMPMIC+/+ or
TRAMPMIC-/- mice (Fig. 3B, p<0.0001, Chi-square test). Multivariate logistic regression analy-
sis confirmed that the increased proportion of TRAMPfmsmic-1 mice with metastases was
Fig 2. TRAMPMIC-/- mice have comparatively larger prostate tumor than TRAMPMIC+/+ mice. The corrected tumor weights of (A) GU and (B) prostates
were compared in TRAMPMIC+/+ and TRAMPMIC-/- mice (n = 22/group/time point) sacrificed at 8, 17, 25 and 33 weeks of age. Results were analyzed using a
2 way ANOVA and are presented as mean ± SEM. p values are shown as *, p< 0.05.
doi:10.1371/journal.pone.0115189.g002
MIC-1/GDF15 and Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0115189 February 19, 2015 7 / 12
independent of their longer survival times (p>0.5) and only dependent on genotype
(p<0.0001). Further, using a similar approach, the lack of difference in the proportion of
TRAMPMIC-/- compared with TRAMPMIC+/+ mice with metastases, could not be accounted for
by their shorter survival (p>0.5).
Discussion
This study clearly indicates that germline deletion of the MIC-1/GDF15 leads to increased
local primary tumor growth resulting in earlier death of TRAMP PCa prone mice. These data
Fig 3. Effect ofMIC-1/GDF15 genemodification onmetastases. (A) Survival data for TRAMPMIC+/+
(n = 63), TRAMPMIC-/- (n = 63) and TRAMPfmsmic-1 (n = 63) mice is presented as a Kaplan-Meier plot and the
log-rank statistic for median survival time is shown. (B) Comparison between number of TRAMPMIC+/+
(n = 63), TRAMPMIC-/- (n = 63) and TRAMPfmsmic-1 (n = 63) mice having distant organ metastases at the time
of death has been analyzed using the Chi-squared test.
doi:10.1371/journal.pone.0115189.g003
MIC-1/GDF15 and Prostate Cancer
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are consistent with our previous publication indicating that transgenic overexpression of
MIC-1/GDF15 decreases local PCa tumor growth and substantially increases survival of
TRAMP mice. This result is consistent with results in another transgenic model of early cancer
in Apcmin colonic polyp prone mice also overexpressing MIC-1/GDF15 [38]. This reinforces
the argument that MIC-1/GDF15 plays a protective role in early local tumor development and
growth. Several epidemiological studies suggest that this finding may be translated to at least
some human cancers. For example, increased local concentrations of extracellular matrix asso-
ciated MIC-1/GDF15 in prostate cancer biopsies were associated with reduced risk of disease
progression, especially in the subgroup with early cancer and with Gleason grade of 6 or less.
In this group MIC-1/GDF15 localised to the tumor matrix was the single best predictor of
tumor recurrence [28]. In patients from the polyp prevention trial, a higher polyp free serum
MIC-1/GDF15 level afforded protection from polyp recurrence and NSAID mediated protec-
tion was lost if MIC-1/GDF15 serum levels were not elevated with NSAID treatment [39].
The apparently discordant effect of MIC-1/GDF15 on local tumor growth and the metastat-
ic process, that we described previously, is again demonstrated here [43]. Transgenic overex-
pression leads to smaller local tumors and longer survival, as TRAMPcfmsmic-1 mice no longer
die early of local disease. Independently of increased survival time, these same TRAMPcfmsmic-1
mice have more metastases. However, we could demonstrate no difference in the proportion of
mice with metastases between TRAMPMIC+/+ and TRAMPMIC-/- mice. As few mice of either
line developed metastases by the experimental endpoint we may not have studied enough mice
to be certain that no differences exist. Additionally, as prostate tumors in TRAMPMIC+/+ mice
express little MIC-1/GDF15 [43], it may be that this model is more sensitive to the effects of in-
creased expression compared to gene deletion.
Whilst there was no significant difference in metastases between TRAMPMIC+/+ and
TRAMPMIC-/- mice, there may be differences in local invasion. TRAMPMIC-/- mice with larger
prostate tumors had smaller SVs (data not shown), which suggests that there may be less
SV invasion.
HowMIC-1/GDF15 might exert effects on tumor growth and spread is uncertain. Elucidat-
ing its mechanisms of action is greatly hampered because the identity of its receptor is un-
known. It is presumed that the receptor is a member of the highly conserved hetrotetrameric
TGF-b receptor (TBR) superfamily, but there is limited direct evidence for this. There is some
indirect evidence, based on antibody blockade, that it may utilise TBRII [26,45] the class 2 re-
ceptor used by TGF-b itself, but there is no direct biochemical or genetic evidence supporting
this data. The signalling cascade of the receptor complex or class I receptor utilised by MIC-1/
GDF15 is to date, completely unknown.
There is now a plethora of published data on the role of MIC-1/GDF15 on tumor growth
and spread with a confusing range of results. Data from experiments using human cell lines, in
which MIC-1/GDF15 expression has either been induced or knocked down, then xenografted
into immunodeficient mice, have provided sometimes, contradictory results [18,29–34]. Stud-
ies using transgenic models of spontaneously developing cancer that also bear genetically mod-
ified MIC-1/GDF15 expression and an intact immune system all point to a protective role for
MIC-1/GDF15 on local tumor development. A similar effect can also be observed in two mod-
els of carcinogen induced cancer in transgenic mice overexpressing MIC-1/GDF15, which also
have an intact immune system [35,36]. The most parsimonious explanation that may explain
these contradictions is that MIC-1/GDF15 regulates anti-cancer immunity, which in turn regu-
lates cancer growth.
Overall, our results support an important protective role for MIC-1/GDF15 in the develop-
ment and early growth of PCa and probably cancer in general. Unravelling the biological effect
of MIC-1/GDF15 on tumor evolution and biology is of practical importance for several
MIC-1/GDF15 and Prostate Cancer
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reasons. A high proportion of cancers express it, to the extent that serum level can rise up to
10–100 fold and cause cancer anorexia/cachexia. Further, its expression is increased by all can-
cer treatment modalities including surgery, radiotherapy and chemotherapy. Thus any effect
that MIC-1/GDF15 has on local tumor biology, particularly tumor spread is likely to impact
most cancer patients, raising the prospect that modulation of MIC-1/GDF15 actions during
therapy might reduce the risk of metastatic disease and other complications of cancer.
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